<DOC>
	<DOCNO>NCT01524601</DOCNO>
	<brief_summary>Renal transplant recipient need life long immunosuppression one new drug everolimus . Everolimus potent immunosuppressive drug one main side-effects increase blood cholesterol level . Many renal transplant recipient treat cholesterol lower agent , mainly fluvastatin . Rosuvastatin new cholesterol lower drug market potential high cholesterol lower potency . In present study investigator examine hypothesis rosuvastatin reduce cholesterol level fluvastatin renal transplant patient .</brief_summary>
	<brief_title>The Rosuvastatin In TrAnsplant Recipients Study</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Renal transplant recipient stable renal function ( plasma creatinine &lt; 200 Âµmol/L ) Renal transplant recipient everolimus fluvastatin base therapy minimum 3 month prior inclusion &gt; 18 year age Male patient female patient without childbearing potential ( surgically sterilize postmenopausal ) female childbearing potential ; lactate , negative pregnancy test screen willing utilize effective method contraception throughout study period 90 day follow discontinuation study drug Signed informed consent Patients experience acute rejection episode within 2 week inclusion , whether proven biopsy Patients know hypersensitivity rosuvastatin Change enzyme induce inhibit drug within last 2 week prior throughout study [ e.g . barbiturate , rifampicin , ketoconazole , erythromycin , cimetidine similar drug ] Pregnant nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Everolimus</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>fluvastatin</keyword>
	<keyword>Lipid lowering</keyword>
</DOC>